CorMedix Inc. (CRMD)

Market Cap	494.06M -14.2%
Revenue (ttm)	311.71M +617.0%
Net Income	162.07M
EPS	2.04
Shares Out	79.05M
PE Ratio	3.06
Forward PE	7.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,012,929
Open	6.21
Previous Close	6.30
Day's Range	6.16 - 6.33
52-Week Range	5.60 - 17.43
Beta	1.42
Analysts	Strong Buy
Price Target	14.67 (+134.72%)
Earnings Date	Mar 5, 2026

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2010
• Employees: 191
• Stock Exchange: NASDAQ
• Ticker Symbol: CRMD
• Website: https://cormedix.com

Analyst Summary

According to 6 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price target is $14.67, which is an increase of 134.72% from the latest price.

Price Target

$14.67

(134.72% upside)

Analyst Consensus: Strong Buy